In vitro structure-activity relationship of Re-cyclized octreotide analogues

Nuclear Medicine and Biology

Volumn 37, Issue 5, 2010, Pages 527-537

  Dannoon, Shorouk F ^a   Bigott Hennkens, Heather M ^a   Ma, Lixin ^a,b,c   Gallazzi, Fabio ^a   Lewis, Michael R ^a,b,c   Jurisson, Silvia S ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Metal cyclization; Octreotide; Re; Two dimensional NMR

Indexed keywords

OCTREOTIDE; RHENIUM; SOMATOSTATIN RECEPTOR;

ARTICLE; DRUG BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PHARMACOPHORE; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CYCLIZATION; DRUG STABILITY; METABOLISM; PROTEIN SECONDARY STRUCTURE; RAT; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CYCLIZATION; DRUG STABILITY; MODELS, MOLECULAR; OCTREOTIDE; PROTEIN STRUCTURE, SECONDARY; RATS; RECEPTORS, SOMATOSTATIN; RHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953752568     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.008     Document Type: Article

References (35)

1. Hofland L.J., Lamberts S.W.J. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24(1):28-47.
2. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20(3):157-198.
3. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., et al. SMS 201-995: a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci 1982, 31(11):1133-1140.
4. de Herder W.W., Hofland L.J., van der Lely A.J., Lamberts S.W.J. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr-Relat Cancer 2003, 10(4):451-458.
5. Lamberts S.W.J., van Der Lely A.-J., de Herder W.W., Hofland L.J. Octreotide. N Engl J Med 1996, 334(4):246-254.
6. Olsen J.O., Pozderac R.V., Hinkle G., Hill T., O'Dorisio T.M., Schirmer W.J., et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995, 25(3):251-261.
7. Gotthardt M., Boermann O.C., Behr T.M., Behe M.P., Oyen W.J.G. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 2004, 10(24):2951-2963.
8. 1-octreotide. Eur J Nucl Med 2000, 27(10):1580.
9. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003, 44(5):708-716.
10. Giblin M.F., Jurisson S.S., Quinn T.P. Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem 1997, 8(3):347-353.
11. 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res 2000, 60(20):5649-5658.
12. 111In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 2001, 42(12):1847-1855.
13. Cheng Z., Chen J., Quinn T.P., Jurisson S.S. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 2004, 64(4):1411-1418.
14. Bigott-Hennkens H.M., Junnotula S., Ma L., Gallazzi F., Lewis M.R., Jurisson S.S. Synthesis and in vitro evaluation of a rhenium-cyclized somatostatin derivative series. J Med Chem 2008, 51(5):1223-1230.
15. Bigott-Hennkens H.M., Dannoon S.F., Figueroa S.D., Hoffman T.J., Jurisson S.S., Lewis M.R. Biodistribution and imaging studies of somatostatin receptors using technetium-99m-cyclized tyrosine-3-octreotate. Technetium, Rhenium and Other Metals in Chemisty and Nuclear Medicine 2006, vol. 7:295-300. SGE Editoriali, Padova, Italy. U. Mazzi (Ed.).
16. Grove D.E., Wilkinson G Oxo-complexes of rhenium(V). J Chem Soc A, Inorg Phys Theoret 1966, (9):1224-1230.
17. 4. Acta Crystallogr B 1977, B33(4):1248-1250.
18. Pearson D.A., Lister-James J., McBride W.J., Wilson D.M., Martel L.J., Civitello E.R., et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 1996, 39(7):1361-1371.
19. Cyr J.E., Pearson D.A., Wilson D.M., Nelson C.A., Guaraldi M., Azure M.T., et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem 2007, 50(6):1354-1364.
20. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 1995, 6(3):277-293.
21. 15N chemical shift referencing in biomolecular NMR. J Biomol NMR 1995, 6(2):135-140.
22. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003, 30(6):917-920.
23. 2: an in vitro/in vivo structure-activity relationship study where X=0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 2003, 14(1):93-102.
24. Ma L., Jones C.T., Groesch T.D., Kuhn R.J., Post C.B. Solution structure of dengue virus capsid protein reveals another fold. Proc Natl Acad Sci USA 2004, 101(10):3414-3419.
25. Schwieters C.D., Kuszewski J.J., Tjandra N., Marius Clore G. The Xplor-NIH NMR molecular structure determination package. J Magn Reson 2003, 160(1):65-73.
26. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998, 95(22):12814-12818.
27. Grace C.R.R., Erchegyi J., Koerber S.C., Reubi J.C., Rivier J., Riek R. Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem 2006, 49(15):4487-4496.
28. Wuthrich K. NMR of Proteins and Nucleic Acids 1986, 166. John Wiley & Sons, New York.
29. Wynants C., Tourwe D., Kazmierski W., Hruby V.J., Van Binst G. Conformation of two somatostatin analogs in aqueous solution. Study by NMR methods and circular dichroism. Eur J Biochem 1989, 185(2):371-381.
30. Wynants C., Van Binst G., Loosli H.R. Hexapeptide analog of somatostatin, Sandoz 201-456. Conformational study in dimethylsulfoxide by 1D and 2D n.m.r. methods. Int J Pept Protein Res 1985, 25(6):622-627.
31. Wynants C., Van Binst G., Loosli H.R. SMS 201-995, an octapeptide somatostatin analog. Assignment of the proton 500 MHz n.m.r. spectra and conformational analysis of SMS 201-995 in dimethylsulfoxide. Int J Pept Protein Res 1985, 25(6):615-621.
32. Wynants C., Van Binst G., Michel A., Zanen J. Assignment of the proton 500 MHz NMR spectra of a synthetic eight-membered ring analog of somatostatin in aqueous solution. Int J Pept Protein Res 1985, 26(6):561-567.
33. Widmer H., Widmer A., Braun W. Extensive distance geometry calculations with different NOE calibrations: new criteria for structure selection applied to Sandostatin and BPTI. J Biomol NMR 1993, 3(3):307-324.
34. Pohl E., Heine A., Sheldrick G.M., Dauter Z., Wilson K.S., Kallen J., et al. Structure of octreotide, a somatostatin analog. Acta Crystallogr D Biol Crystallogr 1995, D51(1):48-59.
35. Melacini G., Zhu Q., Goodman M. Multiconformational NMR analysis of Sandostatin (octreotide): equilibrium between beta-sheet and helical structures. Biochemistry 1997, 36(6):1233-1241.